Skip to main content

CORRECTION article

Front. Microbiol., 25 July 2023
Sec. Antimicrobials, Resistance and Chemotherapy

Corrigendum: Cathelicidin-derived antiviral peptide inhibits herpes simplex virus 1 infection

\r\nXiaomin Guo&#x;Xiaomin Guo1Yanxing An&#x;Yanxing An1Wanmin TanWanmin Tan2Ling MaLing Ma2Mingyang WangMingyang Wang2Juyan LiJuyan Li2Binghong LiBinghong Li2Wei HouWei Hou1Li Wu
Li Wu2*
  • 1College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China
  • 2Department of Medical Imaging, First Affiliated Hospital of Kunming Medical University, Kunming, China

A corrigendum on
Cathelicidin-derived antiviral peptide inhibits herpes simplex virus 1 infection

by Guo, X., An, Y., Tan, W., Ma, L., Wang, M., Li, J., Li, B., Hou, W., and Wu, L. (2023). Front. Microbiol. 14:1201505. doi: 10.3389/fmicb.2023.1201505

In the published article, there was a typographical error that stated that the dose of HSV-1 in ocular scarification mice was 5 × 104 PFU, which should have been 4 × 104 PFU.

A correction has been made to 2. Materials and methods, 2.7. Mice infection, Paragraph 1. This sentence previously stated:

“The infection dose of HSV-1 was 5 × 104 plaque forming units (PFU).”

The corrected sentence appears below:

“The infection dose of HSV-1 was 4 × 104 plaque forming units (PFU).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: cathelicidins, antiviral peptide, HSV-1, facial palsy, WL-1

Citation: Guo X, An Y, Tan W, Ma L, Wang M, Li J, Li B, Hou W and Wu L (2023) Corrigendum: Cathelicidin-derived antiviral peptide inhibits herpes simplex virus 1 infection. Front. Microbiol. 14:1254775. doi: 10.3389/fmicb.2023.1254775

Received: 07 July 2023; Accepted: 10 July 2023;
Published: 25 July 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Guo, An, Tan, Ma, Wang, Li, Li, Hou and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Li Wu, wuli211@163.com

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.